Company intelligence / Profile preview

Arrow Therapeutics

Ownership: Private
Employees: ~57
Development stage: Other

Overview

Prior to its acquisition by AstraZeneca in early 2007, Arrow Therapeutics developed several antiviral candidates. Its lead compound RSV604 for RSV reached Phase II clinical studies and was partnered with Novartis. The HCV portfolio included NS5a inhibitors such as A‑831 (Phase I) and A‑689 (preclinical). Post-acquisition development continued under AstraZeneca’s direction.[1][4]

Clinical results showed progress through early-stage trials but no independent commercial launches as a standalone company.

Therapeutic areas: Infectious Diseases
Modalities: Small molecules[1][4]genome-based target discovery technology[2]
Industry: Biotech

Partnerships

Novartis (partnered on RSV604 development prior to acquisition)[4].Beactica AB (drug discovery collaboration announced November 2007).[1]

Beyond the preview

Go deeper on Arrow Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Arrow Therapeutics.